Patents by Inventor Dhanabalan Murali
Dhanabalan Murali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6169080Abstract: This invention relates to novel derivatives of camptothecin, and will, particularly to derivatives having a substitution at the C-7 position, or at one of the C-9, C-10, C-11 or C-12 positions, or to disubstituted derivatives having a first substitution at C-7 and a second at one of C-9, C-10, C-11 or C-12. The invention also includes methods of using the compounds as Topoisomerase I inhibitors to treat patients with cancer. The invention also includes pharmaceutical formulations which consist of the novel compounds in solution or suspension with one or more pharmaceutical excipients or dilutes.Type: GrantFiled: February 11, 1998Date of Patent: January 2, 2001Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, P. Seetharamulu, Dasharatha G. Reddy, Shijie Yao, Pavankumar N.V. Petluru, Dhanabalan Murali
-
Patent number: 6040330Abstract: A pharmaceutical formulation of a taxane antineoplastic agent, particularly paclitaxel or docetaxel or a pharmaceutically acceptable salt thereof, and N-methylpyrrolidin-2-one (NMP). The formulation may include other excipients and/or diluents, and is suitable for administration to patients with cancer.Type: GrantFiled: January 8, 1999Date of Patent: March 21, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Fredrick H. Hausheer, Dhanabalan Murali, Peddaiahgari Seetharamulu
-
Patent number: 6037336Abstract: To reduce the toxic effect of carboplatin, particularly myelosuppression and emesis, a dithioether having the formula R.sub.1 -(CH.sub.2).sub.n --S--S--(CH.sub.2).sub.m --R.sub.2 (I) wherein:each of R.sub.1 and R.sub.2 individually is SO.sub.3 H or PO.sub.3 H.sub.2 ; andeach of m and n is individually 1, 2, 3 or 4;or a pharmaceutically acceptable salt thereof, preferably disodium 2,2'-dithiobis(ethane sulfonate) (dimesna), is administered in combination with carboplatin to a patient, at substantially the same time or sequentially, whereby the dithioether and the carboplatin become co-present in the blood of the patient. Compositions comprising carboplatin and the dithioether are included in the invention.Type: GrantFiled: May 10, 1999Date of Patent: March 14, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Seetharamulu Peddaiahgari, Dasharatha G. Reddy
-
Patent number: 6028078Abstract: Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The formula I compounds are highly lipophilic, lactone stable, do not require metabolic activation, and are potent antineoplastic compounds.Type: GrantFiled: October 26, 1998Date of Patent: February 22, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Pavankumar N. V. Petluru, Dasharatha Reddy, Dhanabalan Murali, Kochat Haridas, Peddaiahgari Seetharamulu, Shijie Yao
-
Patent number: 5958937Abstract: A- and/or B-ring substituted camptothecin derivatives, which are poorly water soluble (less than 5 micrograms per milliliter of water), are highly lipophilic camptothecin derivatives (HLCD) and are very active against a variety of human cancers. Because of their very poor water solubility, HLCD have not been used to treat human patients with cancer due to the inability to administer sufficient quantities of the HLCD dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable HLCD formulations for the direct administration of HLCD to human patients with cancer. The claimed invention also describes the methods to create solutions of HLCD and antitumor compositions of HLCD to allow the administration of HLCD in sufficient amounts to treat human patients with various types of cancer.Type: GrantFiled: October 22, 1997Date of Patent: September 28, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5955467Abstract: A- and/or B-ring substituted camptothecin derivatives, which are poorly water soluble (less than 5 micrograms per milliliter of water), are highly lipophilic camptothecin derivatives (HLCD) and are very active against a variety of human cancers. Because of their very poor water solubility, HLCD have not been used to treat human patients with cancer due to the inability to administer sufficient quantities of the HLCD dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable HLCD formulations for the direct administration of HLCD to human patients with cancer. The claimed invention also describes the methods to create solutions of HLCD and antitumor compositions of HLCD to allow the administration of HLCD in sufficient amounts to treat human patients with various types of cancer.Type: GrantFiled: October 22, 1997Date of Patent: September 21, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5935967Abstract: Pharmaceutical formulations of highly lipophilic, poorly water soluble derivatives of Camptothecin are disclosed. The formulations include an effective amount of the HLCD dissolved or suspended in an appropriate amount of N-methyl-2-pyrrolidinone (NMP), and one or more pharmaceutically acceptable excipients.Type: GrantFiled: January 20, 1998Date of Patent: August 10, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5910491Abstract: Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The formula I compounds are highly lipophilic, lactone stable, do not require metabolic activation, and are potent antineoplastic compounds.Type: GrantFiled: August 19, 1997Date of Patent: June 8, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Pavankumar N.V. Petluru, Dasharatha Reddy, Dhanabalan Murali, Kochat Haridas, Peddaiahgari Seetharamulu, Shijie Yao
-
Patent number: 5902610Abstract: This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate is used to reduce the risk or prevent or retard the development of cisplatin induced nephrotoxicity, myelosuppression, and neurotoxicity, and wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate potentiates the antitumor activity of cisplatin when treating human patients with cancer. This invention also teaches novel formulations containing 2,2'-dithio-bis-ethane sulfonate alone or in combination with cisplatin in lyophilized or dissolved in an aqueous formulations which can be administered to patients with cancer who are being treated with cisplatin.Type: GrantFiled: November 3, 1995Date of Patent: May 11, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick Herman Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy, Seetharamulu Peddaiahgari
-
Patent number: 5900419Abstract: A- and/or B-ring substituted camptothecin derivatives, which are poorly water soluble (less than 5 micrograms per milliliter of water), are highly lipophilic camptothecin derivatives (HLCD) and are very active against a variety of human cancers. Because of their very poor water solubility, HLCD have not been used to treat human patients with cancer due to the inability to administer sufficient quantities of the HLCD dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable HLCD formulations for the direct administration of HLCD to human patients with cancer. The claimed invention also describes the methods to create solutions of HLCD and antitumor compositions of HLCD to allow the administration of HLCD in sufficient amounts to treat human patients with various types of cancer.Type: GrantFiled: October 22, 1997Date of Patent: May 4, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5880133Abstract: Pharmaceutical formulations of Highly Lipophilic Camptothecin Derivatives (HLCD) include HLCD dissolved in N-methyl Pyrrolidinene (NMP). The formulations also include quantities of pharmaceutically acceptable excipients and diluents incorporated thereinto.Type: GrantFiled: June 21, 1996Date of Patent: March 9, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5866615Abstract: This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate is used to reduce the risk or prevent or retard the development of cisplatin induced nephrotoxicity, myelosuppression, and neurotoxicity, and wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate potentiates the antitumor activity of cisplatin when treating human patients with cancer. This invention also teaches novel formulations containing 2,2'-dithio-bis-ethane sulfonate alone or in combination with cisplatin in lyophilized or dissolved in an aqueous formulations which can be administered to patients with cancer who are being treated with cisplatin.Type: GrantFiled: April 30, 1997Date of Patent: February 2, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick Herman Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy, Seetharamulu Peddaiahgari
-
Patent number: 5866617Abstract: This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate is used to reduce the risk or prevent or retard the development of cisplatin induced nephrotoxicity, myelosuppression, and neurotoxicity, and wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate potentiates the antitumor activity of cisplatin when treating human patients with cancer. This invention also teaches novel formulations containing 2,2'-dithio-bis-ethane sulfonate alone or in combination with cisplatin in lyophilized or dissolved in an aqueous formulations which can be administered to patients with cancer who are being treated with cisplatin.Type: GrantFiled: April 18, 1997Date of Patent: February 2, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick Herman Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy, Seetharamulu Peddaiahgari
-
Patent number: 5866169Abstract: This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate is used to reduce the risk or prevent or retard the development of cisplatin induced nephrotoxicity, myelosuppression, and neurotoxicity, and wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate potentiates the antitumor activity of cisplatin when treating human patients with cancer. This invention also teaches novel formulations containing 2,2'-dithio-bis-ethane sulfonate alone or in combination with cisplatin in lyophilized or dissolved in an aqueous formulations which can be administered to patients with cancer who are being treated with cisplatin.Type: GrantFiled: June 18, 1997Date of Patent: February 2, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick Herman Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy, Seetharamulu Peddaiahgari
-
Patent number: 5859022Abstract: A- and/or B-ring substituted camptothecin derivatives, which are poorly water soluble (less than 5 micrograms per milliliter of water), are highly lipophilic camptothecin derivatives (HLCD) and are very active against a variety of human cancers. Because of their very poor water solubility, HLCD have not been used to treat human patients with cancer due to the inability to administer sufficient quantities of the HLCD dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable HLCD formulations for the direct administration of HLCD to human patients with cancer. The claimed invention also describes the methods to create solutions of HLCD and antitumor compositions of HLCD to allow the administration of HLCD in sufficient amounts to treat human patients with various types of cancer.Type: GrantFiled: October 22, 1997Date of Patent: January 12, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5859023Abstract: A- and/or B-ring substituted camptothecin derivatives, which are poorly water soluble (less than 5 micrograms per milliliter of water), are highly lipophilic camptothecin derivatives (HLCD) and are very active against a variety of human cancers. Because of their very poor water solubility, HLCD have not been used to treat human patients with cancer due to the inability to administer sufficient quantities of the HLCD dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable HLCD formulations for the direct administration of HLCD to human patients with cancer. The claimed invention also describes the methods to create solutions of HLCD and antitumor compositions of HLCD to allow the administration of HLCD in sufficient amounts to treat human patients with various types of cancer.Type: GrantFiled: October 22, 1997Date of Patent: January 12, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5789000Abstract: This invention describes a novel formulation containing both cis-diammine dichloro platinum and a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate in the same solution, wherein the presence of the disulfide and the parenteral administration of the formulation reduces the risk of cisplatin induced nephrotoxicity when treating human patients with cancer.Type: GrantFiled: November 14, 1994Date of Patent: August 4, 1998Assignee: Bionumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy, Peddaiahgari Seetharamulu
-
Patent number: 5726181Abstract: A- and/or B-ring substituted camptothecin derivatives, which are poorly water soluble (less than 5 micrograms per milliliter of water), are highly lipophilic camptothecin derivatives (HLCD) and are very active against a variety of human cancers. Because of their very poor water solubility, HLCD have not been used to treat human patients with cancer due to the inability to administer sufficient quantities of the HLCD dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable HLCD formulations for the direct administration of HLCD to human patients with cancer. The claimed invention also describes the methods to create solutions of HLCD and antitumor compositions of HLCD to allow the administration of HLCD in sufficient amounts to treat human patients with various types of cancer.Type: GrantFiled: June 5, 1995Date of Patent: March 10, 1998Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy